| Detected | Trial | Change |
|---|---|---|
| 2026-08-14 | NCT06016738 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced… |
Enrollment closed, study ongoing |
| 2026-08-14 | NCT06016738 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced… |
date change Primary completion pushed: 2026-06-30 -> 2026-10-31 |
| 2026-08-14 | NCT06016738 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced… |
date change Completion pushed: 2027-09-30 -> 2028-02-29 |
| 2026-07-19 | NCT07085767 Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2… |
Trial sites expanded: 150 -> 167 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07085767 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2… | Breast Cancer | Recruiting |
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced… | Breast Cancer | Active, Not Recruiting |
| Phase 1 | |||
| NCT06784193 | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) | Recruiting |
| NCT05508906 | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib… | Metastatic Breast Cancer | Recruiting |
| NCT05266105 | A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast… | Breast Cancer | Active, Not Recruiting |